Anlotinib-induced acute renal failure, liver dysfunction, and thrombocytopenia
10.3760/cma.j.cn114015-20240508-00312
- VernacularTitle:安罗替尼致急性肾衰竭并肝功能异常和血小板减少症
- Author:
Xingdong WANG
1
;
Can YAO
;
Boxia LI
;
Rongzhen WANG
;
Yuhui WEI
Author Information
1. 兰州大学第一医院药剂科，兰州 730000
- Publication Type:Journal Article
- Keywords:
Acute renal failure;
Thrombocytopenia;
Liver dysfunction;
Anlotinib;
Tyrosine kinase inhibitors;
Antineoplastic agents
- From:
Adverse Drug Reactions Journal
2024;26(8):499-501
- CountryChina
- Language:Chinese
-
Abstract:
A 59-year-old female patient with lung cancer developed chest tightness, shortness of breath, fatigue, and oliguria after 2 cycles of anlotinib standard regimen. Laboratory tests showed serum creatinine 995.5 μmol/L, urea nitrogen 18.9 mmol/L, blood uric acid 637 μmol/L, 24-hour urine output 400 ml, blood potassium 3.63 mmol/L, alanine aminotransferase (ALT) 957 U/L, aspartate aminotransferase (AST) 32 U/L, total bilirubin 38.8 μmol/L, and platelet count 49×10 9/L. Acute renal failure, liver dysfunction, and thrombocytopenia was diagnosed. The auxiliary examination results excluded the possible progression of underlying diseases. The clinical manifestations of the patient were time-dependent with oral administration of anlotinib. Anlotinib was discontinued and symptomatic treatments such as hemodialysis, liver protection, and diuresis were given. After 14 days, chest tightness, shortness of breath, and fatigue were significantly relieved. Laboratory tests showed serum creatinine 480.3 μmol/L, urea nitrogen 16.2 mmol/L, blood uric acid 414 μmol/L, 24-hour urine output 1 700 ml, blood potassium 3.18 mmol/L, ALT 45 U/L, AST 31 U/L, total bilirubin 37.4 μmol/L, and platelet count 81×10 9/L.
